Alphamab seals $2.2 billion licensing deal with AI biotech
The Chinese drug firm has chosen to partner with an AI specialist rather than Big Pharma on a dual-target cancer therapy, netting an upfront payment of $125 million Key Takeaways:…
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
Despite already having three products on the market, unlike many of its Hong Kong-listed peers, the drug maker is struggling to cover its daily operational costs Key Takeaways: Mabwell said…
Recent Articles
RELATED ARTICLES
-
Mega licensing deal lifts 3SBio profits but core sales slip
-
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
688506.SHG
- Innovent’s $10.5 billion deal marks new model for China drugmakers
- Jacobio Pharma poised to turn a profit from precision cancer drugs
- A healthy return: drug spin-off nets Keymed up to $320 million
- Insilico revenue soars above $100 million on AI drug partnerships
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG
